• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
1.30% $1.14

MESOBLAST LIMITED - Corporate Spotlight

Market Cap $1.304B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

No Corporate Spotlight currently available.

(20min delay)
Last
$1.14 		Change
-0.015(1.30%) 		Mkt cap ! $1.304B
Open High Low Value Volume
$1.15 $1.16 $1.13 $1.950M 1.707M

Buyers (Bids)

No. Vol. Price($)
20 71883 $1.14
 

Sellers (Offers)

Price($) Vol. No.
$1.14 51412 22
View Market Depth
Last trade - 14.36pm 22/07/2024 (20 minute delay) ?
Last
$1.14 		  Change
-0.015 ( 1.65 %)
Open High Low Volume
$1.15 $1.16 $1.13 399949
Last updated 14.57pm 22/07/2024 ?
MSB (ASX) Chart

Top Stories

High-grade copper results provide some relief to 29Metals after earlier mine shutdown

29Metals Ltd has reported positive results from a 3-hole program of drilling in Queensland, finding up to 4.8% copper.
HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group Pacific Smiles Group has confirmed 10% shareholder HBF – the private health insurer – will vote in favour of PSQ's buyout by NDC BidCo.
Biden's exit bakes in a Kamala Harris ballot while markets expect Trump to win. How could equities fare this week? Joe Biden, current US President, has agreed to drop out of the 2024 Presidential election following internal disagreement.
Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in Pure Hydrogen has confirmed it's executed an MOU with a Vietnam-based entity to develop hydrogen-fuelled buses.
Large fault structure and uranium anomalies picked up by Infini at Newfoundland play Infini Resources Ltd has revealed the presence of a large fault structure connected to anomalies at its Portland Creek uranium project.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.